SCHEMBL12875720

SCHEMBL12875720

Cc1cccc(-c2cnc(Cn3cc(C(=O)O)cn3)s2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B1 P14061 2/20 0.47
HSD17B2 P37059 2/20 0.47
ERCC5 P28715 1/20 0.43
FEN1 P39748 1/20 0.43
HSD17B13 Q7Z5P4 1/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
POLB P06746 2/20 0.41
TDP1 Q9NUW8 1/20 0.41
EGLN1 Q9GZT9 1/20 0.41
HCRTR1 O43613 1/20 0.41
HCRTR2 O43614 1/20 0.41
KDM5A P29375 1/20 0.40
KDM4C Q9H3R0 1/20 0.40
KDM5B Q9UGL1 1/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
LOXL2 Q9Y4K0 2/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
KDM4E B2RXH2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12875718 0.88 JMJD6 (0.46) HSD17B1HSD17B2HSD17B13L3MBTL1TDP1
SCHEMBL1198441 0.85 MEN1 (0.50) ERCC5FEN1L3MBTL1POLBTDP1
SCHEMBL12875782 0.83 EP300 (0.44) HSD17B1HSD17B2ERCC5L3MBTL1POLB
SCHEMBL12876572 0.83 L3MBTL1 (0.40) HSD17B1HSD17B2ERCC5L3MBTL1POLB
SCHEMBL1198947 0.82 KMO (0.44) L3MBTL1POLBTDP1EGLN1KDM4C
SCHEMBL12875723 0.80 HCRTR1 (0.43) HSD17B1HSD17B2L3MBTL1POLBTDP1
SCHEMBL12875682 0.80 SIRT5 (0.44) L3MBTL1POLBHDAC6MEN1KMT2A
SCHEMBL12876527 0.78 HCRTR1 (0.41) ERCC5L3MBTL1POLBTDP1EGLN1
SCHEMBL12876169 0.78 KLKB1 (0.39) L3MBTL1POLBTDP1EGLN1HCRTR1
SCHEMBL12875936 0.77 RARA (0.43) L3MBTL1POLBTDP1EGLN1HCRTR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF PDE3B, PDE5A, PDE2A HSD17B1 248/4885HSD17B2 220/4885ERCC5 3907/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.